Showing results (1411-1420 of 1,497) with videos related to
Sort By:
Pageof 150
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 19, 2025
Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancerChao Chen, Jie Chen, Jin Huang, et al.The Lancet. Oncology|December 5, 2024
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.Journal of Inherited Metabolic Disease|October 18, 2019
A study on a cohort of 301 Chinese patients with isolated methylmalonic acidemiaLulu Kang, Yupeng Liu, Ming Shen, et al.Journal of Cancer|August 19, 2017
DNA-dependent protein kinase catalytic subunit functions in metastasis and influences survival in advanced-stage laryngeal squamous cell carcinomaSha-Sha He, Yong Chen, Xiao-Ming Shen, et al.Experimental Cell Research|May 20, 2023
Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer modelLing-Ming Tseng, Ka-Yi Lau, Ji-Lin Chen, et al.Neurology|September 18, 2020
Analysis of 70 patients with hydrocephalus due to cobalamin C deficiencyRuxuan He, Hongwu Zhang, Lulu Kang, et al.Theranostics|March 23, 2021
NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisinDong-Jie Li, Si-Jia Sun, Jiang-Tao Fu, et al.Journal of Cancer|November 21, 2017
Loss of LKB1 Expression Decreases the Survival and Promotes Laryngeal Cancer MetastasisSha-Sha He, Yong Chen, Hong-Zhi Wang, et al.Future Oncology (London, England)|June 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCCJean-Pascal Machiels, Jérôme Fayette, Robert Haddad, et al.Pageof 150